Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems.
about
Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular PressureLoteprednol and tobramycin in combination: a review of their impact on current treatment regimens.C-ring cannabinoid lactones: a novel cannabinergic chemotype.Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation.Topical Ocular Drug Delivery to the Back of the Eye by Mucus-Penetrating Particles.Phase I and phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery.Controlled-deactivation cannabinergic ligands.NANOTECHNOLOGY IN THE TREATMENT AND DETECTION OF INTRAOCULAR CANCERS.Management of seasonal allergic conjunctivitis: guide to therapy.Prodrug strategies in ocular drug delivery.Delivery systems and local administration routes for therapeutic siRNA.Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery.Carbonyl reduction pathways in drug metabolism.Recent trends in drug delivery system using protein nanoparticles.Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same?Chemical delivery systems and soft drugs: Retrometabolic approaches of drug design.Advances in the use of prodrugs for drug delivery to the eye.Ocular non-P450 oxidative, reductive, hydrolytic, and conjugative drug metabolizing enzymes.Nanomicelles: an emerging platform for drug delivery to the eye.Symptomatic Treatment of Subepithelial Infiltrates after Viral Conjunctivitis: Loteprednol or Dexamethasone?Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate.Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%).Cyclosporine A-Loaded Solid Lipid Nanoparticles: Ocular Tolerance andIn VivoDrug Release in Rabbit Eyes
P2860
Q26764956-55FA5225-59F5-44EB-859A-20509827CEAAQ33538277-83171313-1C01-484F-9243-43EA4F75D577Q33636166-284EA93D-230E-4D90-B038-F53641A32609Q34627019-2527994C-8358-42D5-BE02-60EC564B079EQ35759073-9F28C389-1D29-4EBE-AA52-9652FC8B1329Q36939218-52757249-7BA9-4461-B89E-B59EDA8502BEQ37527191-BE364B59-4AAB-4F26-A906-FBF7F35AA5D5Q37776418-79CA8F3C-14F2-4320-AE6F-D84FFDDC3D88Q37954005-518E69F2-E1F1-4D94-A215-3D77FF57415AQ38005228-AF8101D6-DB2D-4CA0-AFC1-F3F4962AA727Q38076344-F57410F0-4F1A-4719-8223-9738D005A80DQ38112375-04E186E8-53A8-4100-8343-19788C0485EFQ38156452-BDCBA102-A229-4E88-BF5F-7A1A6D7C9DD1Q38199373-5412EBF3-9E08-410F-8815-C4F45AD00B83Q38241140-11181884-930A-4F22-A873-C66C3FFDD13AQ38243778-706896FF-8246-4C7A-BD6D-358027F4D942Q38904119-2339DCF5-2CC9-4F3E-8F9C-DEE25B3AD819Q39259079-BFA190C3-1E00-4A11-A0AB-5CDDDF31611AQ39867514-F6A97DF7-E1AC-426F-A85A-B04BA7F8C44DQ40833011-674675F2-3191-4A3C-8410-5CE90EDBDCECQ42103396-CB7B6C67-A57A-454B-9B88-D2DEBA71A4C0Q42795795-4BF58F35-F4C3-440D-A006-3C43A964D0D5Q59155923-FE1C9725-04AE-479E-9CB0-95638F9A9B9E
P2860
Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Ophthalmic drug design based o ...... and chemical delivery systems.
@ast
Ophthalmic drug design based o ...... and chemical delivery systems.
@en
type
label
Ophthalmic drug design based o ...... and chemical delivery systems.
@ast
Ophthalmic drug design based o ...... and chemical delivery systems.
@en
prefLabel
Ophthalmic drug design based o ...... and chemical delivery systems.
@ast
Ophthalmic drug design based o ...... and chemical delivery systems.
@en
P2860
P356
P1433
P1476
Ophthalmic drug design based o ...... and chemical delivery systems
@en
P2093
Nicholas Bodor
P2860
P2888
P304
P356
10.1208/AAPSJ070479
P407
P577
2005-12-07T00:00:00Z
P5875
P6179
1009505170